NCT05995418 Study on the Health Economic Burden of Alzheimer's Disease in China
| NCT ID | NCT05995418 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 9,510 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9,510 participants in total. It began in 2023-07-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.
Eligibility Criteria
Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD. 2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction. 4.Participants or their legal representatives sign informed consent. Exclusion criteria 1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2). 2. Presence of mental or neurological developmental delay. 3. Presence of other known conditions that may cause cognitive impairment. 4. Diagnosis of a disease that prevents completion of cognitive assessments. 5. Refusal to sign informed consent at baseline.
Frequently Asked Questions
Who can join the NCT05995418 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 100 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05995418 currently recruiting?
Yes, NCT05995418 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xuanwu Hospital, Beijing to inquire about joining.
Where is the NCT05995418 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05995418 clinical trial?
NCT05995418 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 9,510 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.